U.S. Hepatitis C Market

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

This research service covers the U.S. hepatitis C (HCV) market from 2008 to 2016, with 2010 as the base year.  Included are products on the market, products in development, and patient and revenue forecasts.  Market challenges, drivers, and restraints are identified and assessed.  The market is segmented by classes of drug: interferons, protease inhibitors, nucleotide polymerase inhibitors, non-nucleotide polymerase inhibitors, NS5a's, and other classes. Included are examinations of therapeutic candidates on the market and in the HCV late-stage pipeline.

Table of Contents

U.S. Hepatitis C Market, Hepatitis C Market Analysis of the U.S. Hepatitis C MarketResearch Service

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.